First-in-human trial results of RET targeted BLU-667

Bookmark and Share
Published: 25 Apr 2018
Views: 4227
Rating:
Save
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Dr Subbiah speaks with ecancer at AACR 2018 about results from a first-in-human clinical trial of RET targeted therapy.

RET alterations occur in tumours of many origins, and is currently treated with non-selective multi kinase inhibitors.

Among 43 patients with advanced solid tumours, BLU-667 elicited response rates of between 30-45%, depending on disease type.

The results are published in Cancer Discovery, and you can watch Dr Subbiah present the results in a press session here.